drugset / Trial / NCT03168035
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerated dose of NC-4016 that can be given to patients with advanced solid tumors or lymphoma. The safety of the drug will also be studied.
Timeline
- Start
- 2013-11
- Primary completion
- 2017-04
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NC-4016 | Unknown | 10 mg/m2 | Intravenous |
| Subject | NC-4016 | Unknown | 15 mg/m2 | Intravenous |
| Subject | NC-4016 | Unknown | 25 mg/m2 | Intravenous |
| Subject | NC-4016 | Unknown | 30 mg/m2 | Intravenous |
| Subject | NC-4016 | Unknown | 40 mg/m2 | Intravenous |
| Subject | NC-4016 | Unknown | 60 mg/m2 | Intravenous |
| Subject | NC-4016 | Unknown | 80 mg/m2 | Intravenous |